A Note from the KidneyCAN President:
Thank You for Being Here
|
|
As we continue emerging from our Covid challenges, I want to thank all those who have supported KidneyCAN in 2021. We are a small, nimble team of passionate and dedicated warriors determined to accelerate cures for kidney cancer. Your support makes this possible.
Whether you attended a KidneyCAN event, served as an advocate, donated money, or simply read our newsletters and followed us on social media -- your being here matters, and we are glad to have you.
Thank you again, and I look forward to collaborating with you in 2022 as we accelerate cures for kidney cancer.
Sincerely,
|
|
Bryan L. G. Lewis,
President
|
|
Asking Congress to Fund Kidney Cancer Research:
KidneyCAN Fall Advocacy Micro-Strike
|
|
On Monday, December 1, 2021, KidneyCAN gathered a team of delegates and once again asked Congress to fund kidney cancer research. We are asking for robust funding of the Congressionally Directed Medical Research Programs, and for money specifically directed to kidney cancer research.
We're optimistic about 2022 funding, but with the current Continuing Resolution, funding is frozen until legislation is passed. Read about our efforts and how you can help:
|
|
Save the Date:
Spring Advocacy Days
On March 7-8, we'll start working on FY23 funding. Mark your calendars, and plan to join us!
|
|
KidneyCAN Community Spotlight:
What Cancer Can't Take from Us: David 's Story
|
|
For this month’s Community Spotlight, KidneyCAN spoke to David Roy and Josie Garcia-Roy, both California natives living and working in the Los Angeles area.
David is 37 years old and the co-founder and Chief Client Officer for a digital marketing agency. Josie is an analytics supervisor at a marketing agency. They enjoy an active lifestyle that includes traveling, hiking, and exercising.
David explains that a kidney cancer diagnosis, which came just months after their wedding, upended the newlyweds’ original plans to buy a house and start a family. “You don’t expect to go through this in your thirties. I was diagnosed with a rare subtype of kidney cancer: Xp11 translocation renal cell carcinoma.”
|
|
CURE Magazine: Oncology Nursing Award
Nominate Your Extraordinary Healer
|
|
KidneyCAN partner CURE Magazine® invites you to nominate your oncology nurse for the 2022 Extraordinary Healer Award for Oncology Nursing, a special award that recognizes outstanding oncology nurses who demonstrate compassion, expertise and helpfulness when caring for patients with cancer. Essay nominations will be accepted from healthcare professional colleagues, current or former patients, caregivers, family members and friends. Nominations close on January 15, 2022. Don’t miss out on honoring a special nurse who continues to bring hope and healing to patients with cancer and their loved ones. Join the CURE® community in showing your appreciation today! Submit a nomination today.
|
|
Update: Kidney Cancer Research Program |
|
Kidney cancer consumer advocates recently participated in the evaluation of Congressionally Directed Medical Research Programs' (CDMRP) Kidney Cancer Research Program (KCRP) research applications. As full voting members, along with prominent scientists, these volunteers determined how the $50 million appropriated by Congress for FY'21 will be spent on kidney cancer research.
Many of those in our KidneyCAN community served as consumer reviewers. Thank you for your time and efforts in this regard. COL Sarah Goldman, Director of the CDMRP, says, "We very much value this critical input from our consumers, who help ensure that CDMRP’s work remains critical and relevant."
Read more about the KCRP here:
|
|
Patient Education: The DF/HCC Kidney Cancer Symposium |
|
Thank you to Dana Farber/Harvard Cancer center for organizing this excellent kidney cancer patient education program annually, and for making the recordings available for those unable to attend. |
|
Research Update: Ipi + Nivo for Patients with RCC Brain Metastases
|
|
In patients who had previously untreated aRCC and brain metastases -- a population with a high unmet medical need that often is underrepresented in clinical trials -- the approved regimen of NIVO + IPI followed by NIVO showed encouraging antitumor activity and no new safety signals. |
|
Research Update: New Immunotherapy Insights for Kidney Cancer
|
|
This development is an interesting step forward toward identifying patients most likely to benefit from immunotherapy. In this study, an increased number of specific ‘clonal’ T cell receptors, proteins on the surface of T cells, present in the tumor before treatment, was linked to a greater chance of positive immunotherapy response. If these T cell receptors were maintained during treatment, this was the strongest indicator that treatment would be effective. |
|
Kidney CAN continues our Year-End Giving Campaign for 2021. We have a had a productive and fulfilling year working on behalf of kidney cancer patients, families, and researchers. Please check out our 2021 accomplishments and consider a tax-deductible donation to KidneyCAN.
Our mission is to accelerate cures for kidney cancer. We engage in patient advocacy and power research by supporting government and industry research funding, facilitating research collaborations, and offering direct financial support for clinical and laboratory researchers with promising ideas. Together, we can find the cure.
|
|
Thank you for being part of our grassroots army! |
|
KidneyCAN is a registered 501(c)(3) nonprofit and does not receive any funding through the Congressionally Directed Medical Research Program (CDMRP) or KCRP (Kidney Cancer Research Program). KidneyCAN's work is funded entirely through donations. |
|
|
|
|
|
|
